Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRichard Chen, PA
Clinical InstructorAbout
Research
Publications
2026
Molecular residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: The VICTORI study.
Vasconcelos J, Titmuss E, Navarro F, Ravi N, Abbott C, Hegebarth D, Chia B, Yap M, Lim H, Gill S, Gill K, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Molecular residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: The VICTORI study. Journal Of Clinical Oncology 2026, 44: 3629-3629. DOI: 10.1200/jco.2026.44.16_suppl.3629.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAColorectal cancerResidual diseaseDetection of molecular residual diseaseAssociated with inferior outcomesWeek 4Detection of circulating tumor DNAMedian Follow-UpLoco-regional treatmentProspective observational studyStage I-IIICell-free DNAColorectal cancer patientsColorectal cancer cohortWeeks post-surgeryNeoadjuvant treatmentMRD assaysRectal cancerTumor DNAInferior outcomesCurative treatmentCurative procedureFollow-upColon cancerCirculating tumor DNA to enhance detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy.
Clark H, Lee S, Knisely A, Chen Y, Keough K, Abbott C, Tanguma M, Soliman P, How J, Ramondetta L, Sims T, Boruta D, Westin S, Shafer A, Wilke R, Richardson G, Sood A, Boyle S, Chen R, Jazaeri A. Circulating tumor DNA to enhance detection of high-risk minimal residual disease in ovarian cancer relative to second look laparoscopy. Journal Of Clinical Oncology 2026, 44: 5567-5567. DOI: 10.1200/jco.2026.44.16_suppl.5567.Peer-Reviewed Original ResearchMinimal residual diseaseCirculating tumor DNAHigh-grade epithelial ovarian cancerHigh-grade ovarian cancerEpithelial ovarian cancerOvarian cancerFrontline treatmentResidual diseaseClinical remissionTumor DNAIndependent predictorsIndependent predictors of PFSNegative ctDNAPositive ctDNAMinimal residual disease detectionCtDNA positivityTreatment of ovarian cancerPredictor of PFSConcordant negative resultsPredictors of recurrenceSingle-institution studyTumor-specific variantsIdentification of recurrenceRetrospective cohort studyMRD statusUltra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment.
How J, Zerdan M, Pham M, Xu X, Keough K, Abbott C, Chen Y, Boyle S, Chen R, Celestino N, Westin S, Jazaeri A, Soliman P. Ultra-sensitive circulating tumor DNA (ctDNA) detection as predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment. Journal Of Clinical Oncology 2026, 44: 5611-5611. DOI: 10.1200/jco.2026.44.16_suppl.5611.Peer-Reviewed Original ResearchAssociated with worse RFSCirculating tumor DNASingle-institution prospective studyCirculating tumor DNA analysisCirculating tumor DNA detectionHigh-risk cohortPost-operativelyEC patientsEndometrial cancerMultivariate analysisUltrasensitive rangeAdjuvant therapyTumor DNASurvival outcomesCtDNA detectionCtDNA detection rateAssociated with inferior survivalPredictor of survival outcomesCohort of EC patientsHistological tumor componentsPrimary surgical managementMedian Follow-UpPost-operative time pointsTP53 mutation statusRisk of recurrenceClinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer.
Black J, Wan J, Abbott C, Li B, Karasaki T, Azizi A, Liu L, Lucas O, Grieco C, Leppa A, Al-Bakir M, Liu K, Moore D, Shutkever O, Murphy C, Jamal-Hanjani M, Pyke R, Boyle S, Chen R, Swanton R. Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer. Journal Of Clinical Oncology 2026, 44: 8017-8017. DOI: 10.1200/jco.2026.44.16_suppl.8017.Peer-Reviewed Original ResearchNon-small cell lung cancerCirculating tumor DNARecurrence-free survivalCirculating tumor DNA detectionUndetectable circulating tumour DNAMolecular residual diseaseCell lung cancerOverall survivalClinically high-risk subgroupsPlasma samplesClinical outcomesCtDNA detectionAssociated with inferior recurrence-free survivalClinical validationLung cancerAdjuvant treatment decision-makingInferior recurrence-free survivalPostoperative circulation tumor DNATreated with upfront surgeryEarly-stage NSCLC patientsClinical outcomes of patientsCtDNA positivityPreoperative ctDNA detectionDetection of circulating tumor DNAStage I patientsUltrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy.
Gebhardt C, Koett J, Heidrich I, Abbott C, Keough K, Li B, Keller L, Geidel G, Smit D, Simon R, Chen R, Boyle S, Pantel K. Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy. Journal Of Clinical Oncology 2026, 44: 9572-9572. DOI: 10.1200/jco.2026.44.16_suppl.9572.Peer-Reviewed Original ResearchCirculating tumor DNAMolecular residual diseaseImmune checkpoint inhibitorsCtDNA-positiveAdjuvant settingMelanoma patients treated with immune checkpoint inhibitorsPatients treated with immune checkpoint inhibitorsDetection of molecular residual diseaseBaseline circulating tumour DNADetection of loco-regionalPatients treated with immunotherapyRisk of distant metastasisPrognostic of poor survivalAdaptation of therapeutic strategiesConventional clinicopathological factorsLoco-regional metastasesLiquid biopsy approachRisk of progressionEarly molecular responsePatient-specific variantsAdjuvant cohortAdjuvant patientsCheckpoint inhibitorsDistant relapseMolecular relapseIntegrating circulating tumor DNA and second-look laparoscopy for minimal residual disease detection and survival prediction in ovarian cancer
Clark H, Lee S, Knisely A, Chen Y, Keough K, Abbott C, Rangel K, Tanguma M, Celestino J, Soliman P, How J, Ramondetta L, Sims T, Boruta D, Westin S, Shafer A, Wilke R, Richardson G, Sood A, Boyle S, Chen R, Jazaeri A. Integrating circulating tumor DNA and second-look laparoscopy for minimal residual disease detection and survival prediction in ovarian cancer. Gynecologic Oncology 2026, 208: s71-s72. DOI: 10.1016/j.ygyno.2026.01.1848.Peer-Reviewed Original ResearchMutational patterns in a large cohort of parathyroid carcinomas
Pandya C, Uzilov A, Costa-Guda J, Bellizzi J, Taik P, Moe A, Strahl M, van der Tuin K, Stevenson M, Cavaco B, Cetani F, Marcocci C, Karhu A, Arola J, Schalin-Jäntti C, Morreau H, Thakker R, Schadt E, Sebra R, Li S, Chen R, Arnold A. Mutational patterns in a large cohort of parathyroid carcinomas. Journal Of Endocrinological Investigation 2026, 1-11. PMID: 41879893, DOI: 10.1007/s40618-026-02855-x.Peer-Reviewed Original ResearchParathyroid carcinomaCDC73 mutationsEvaluating patientsSporadic parathyroid carcinomaGermline pathogenic variantsGenotype-phenotype correlationCDC73 geneRecurrent/metastatic diseaseRare malignancyCarcinoma cohortNext-generation DNA sequencingWHO criteriaTargeted therapyClinical featuresTumor typesOncogenic driversPathogenic variantsCarcinomaDriver mutationsPatientsMutation patternsPI3K/mTOR activationIndividualized treatmentCohortPI3K/AKT/mTOR pathwayMonitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Ravi N, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle S, Chen R, Uronis H. Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. Scientific Reports 2026, 16: 14766. PMID: 41872254, PMCID: PMC13168297, DOI: 10.1038/s41598-026-43178-4.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerProgression-free survivalOverall survivalTreatment responseAssociated with worse OSAssociated with worse overall survivalDetection of disease progressionPrediction of treatment responsePhase II trialLiquid biopsy approachMonitoring Treatment ResponseEsophagogastric cancer patientsMedian lead timeLiquid biopsy platformTreatment decision-makingCtDNA dynamicsCtDNA assaysCtDNA levelsII trialTumor sizeBiopsy approachTumor DNAEsophagogastric cancerBiopsy platformTumor samplesThe Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Hunter N, Parsons H, Cope L, Canzoniero J, Navarro F, El-Refai S, Anampa J, Sparano J, Rimawi M, Storniolo A, Mainor C, Nanda R, DeMichele A, Gupta G, Stringer-Reasor E, Lynce F, Cobain E, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang E, Blackwell K, Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow J, Chen R, Boyle S, Stearns V, Wolff A, Park B. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. Journal Of Clinical Oncology 2026, 44: 1283-1295. PMID: 41805422, DOI: 10.1200/jco-25-02934.Peer-Reviewed Original ResearchInvasive disease-free survivalTriple-negative breast cancerPathological complete responseCirculating tumor DNAMinimal residual diseaseDetect circulating tumor DNAPathological response evaluationNon-pCR patientsNeoadjuvant therapyNegative predictive valueTumor DNANon-pCRCtDNA-negativeResidual diseaseBreast cancerHuman epidermal growth factor receptor 2 (HER2)-positiveTNBC cohortHER2-positive breast cancerBiomarkers of treatment responseResponse evaluationTherapeutic de-escalationSecondary objectivesDisease-free survivalSuperior risk stratificationLong-term survivalUltrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
Nishizaki D, Law A, Li B, Abbott C, Chen Y, Lee S, Pyke R, Keough K, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer. Npj Precision Oncology 2026, 10: 79. PMID: 41580469, PMCID: PMC12936199, DOI: 10.1038/s41698-026-01287-3.Peer-Reviewed Original ResearchProgression-free survivalMolecular complete responseImmune checkpoint inhibitorsCtDNA monitoringPrognostic of progression-free survivalPredictor of immunotherapy responseLongitudinal plasma samplesEarly molecular responseBaseline to first follow-upCtDNA clearanceFirst follow-upCheckpoint inhibitorsComplete responseCtDNA assaysICI responseOverall survivalImmunotherapy responseResponse assessmentAdvanced/metastatic cancerClinical decision-makingFollow-upSomatic mutationsAdvanced cancerPlasma samplesPatients